Evidation Health, which helps aggregate health data from wearables and other sources for virtual clinical trials, raises $153M, source says at a $1B+ valuation
Context & Ripple Effects
Evidation Health's $153M round roughly triples down on its $45M Series D from July 2020, also led into virtual-trial infrastructure, and pushes the company past a reported $1B valuation. The raise lands in the middle of a funding wave for the real-world-evidence stack: Aetion closed a $110M Series C two months earlier for validating real-world treatment evidence, HealthVerity raised $100M that summer, and Reify Health went from a $220M Series C to a Series D at a $4.8B+ valuation within eight months.
First-order effects
- Evidation gains unicorn status and fresh capital to scale its core asset — aggregated wearable and consumer health data sold into virtual clinical trials — just as pharma sponsors fund this category heavily.
Second-order effects
- Pharma buyers now face multiple funded, overlapping suppliers (Evidation, HealthVerity, Aetion) for patient-level real-world data, pressuring differentiation toward proprietary datasets and validation methods rather than raw access.
Third-order effects
- If the pattern holds, clinical-trial infrastructure consolidates around data aggregators and analytics validators, shifting trials from site-based recruitment toward decentralized models where consumer devices are the primary evidence source.
The trend: Venture capital is racing to build the real-world-evidence layer that substitutes aggregated consumer health data for physical trial sites.